Business & FinanceTop StoryTop StoryLatest News
HRV Pharma Acquires German Firm Phatebo, Enters Finished Formulations Business
Sentiment: NeutralHigh Priority
What Happened?
Hyderabad-based HRV Pharma has acquired German company Phatebo GmbH, marking its entry into the European finished formulations market. The deal expands HRV's operations beyond active pharmaceutical ingredients.
Key points
- HRV Pharma acquires 100% equity in Phatebo from ZeroStack Corp.
- Phatebo reported revenue of approximately ₹350 crore in 2025.
- The acquisition provides HRV with a licensed operating business in Germany.
- Phatebo specializes in clinical trial supply and sourcing medicines.
- The deal marks HRV's first acquisition in the finished formulations segment in Europe.
Key insights
- The acquisition could enhance HRV's competitive position in the European market.
- Phatebo's established distribution systems may streamline HRV's operations.
- This move may lead to increased collaboration with global pharmaceutical companies.
Why it matters
This acquisition allows HRV Pharma to diversify its business and strengthen its presence in the European pharmaceutical market.
Tags
Entities
HRV Pharma· CompanyPhatebo GmbH· CompanyZeroStack Corp· CompanyGermany· CountryHyderabad· City
Source
Business Standard
